An official website of the United States government
BAP1 is a powerful tumor suppressor gene characterized by haplo insufficiency. Individuals carrying germline BAP1 mutations often develop mesothelioma, an aggressive malignancy of the serosal layers covering the lungs, pericardium, and abdominal cavity. Intriguingly, mesotheliomas developing in carriers of germline BAP1 mutations are less aggressive, and these patients have significantly improved survival. We investigated the apparent paradox of a tumor suppressor gene that, when mutated, causes less aggressive mesotheliomas. We discovered that mesothelioma biopsies with biallelic BAP1 mutations showed loss of nuclear HIF-1α staining. We demonstrated that during hypoxia, BAP1 binds, deubiquitylates, and stabilizes HIF-1α, the master regulator of the hypoxia response and tumor cell invasion. Moreover, primary cells from individuals carrying germline BAP1 mutations and primary cells in which BAP1 was silenced using siRNA had reduced HIF-1α protein levels in hypoxia. Computational modeling and co-immunoprecipitation experiments revealed that mutations of BAP1 residues I675, F678, I679, and L691 -encompassing the C-terminal domain-nuclear localization signal- to A, abolished the interaction with HIF-1α. We found that BAP1 binds to the N-terminal region of HIF-1α, where HIF-1α binds DNA and dimerizes with HIF-1β forming the heterodimeric transactivating complex HIF. Our data identify BAP1 as a key positive regulator of HIF-1α in hypoxia. We propose that the significant reduction of HIF-1α activity in mesothelioma cells carrying biallelic BAP1 mutations, accompanied by the significant reduction of HIF-1α activity in hypoxic tissues containing germline BAP1 mutations, contributes to the reduced aggressiveness and improved survival of mesotheliomas developing in carriers of germline BAP1 mutations.
more »
« less
BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene × environment interaction with asbestos
Carriers of heterozygous germline BAP1 mutations ( BAP1 +/− ) are affected by the “BAP1 cancer syndrome.” Although they can develop almost any cancer type, they are unusually susceptible to asbestos carcinogenesis and mesothelioma. Here we investigate why among all carcinogens, BAP1 mutations cooperate with asbestos. Asbestos carcinogenesis and mesothelioma have been linked to a chronic inflammatory process promoted by the extracellular release of the high-mobility group box 1 protein (HMGB1). We report that BAP1 +/− cells secrete increased amounts of HMGB1, and that BAP1 +/− carriers have detectable serum levels of acetylated HMGB1 that further increase when they develop mesothelioma. We linked these findings to our discovery that BAP1 forms a trimeric protein complex with HMGB1 and with histone deacetylase 1 (HDAC1) that modulates HMGB1 acetylation and its release. Reduced BAP1 levels caused increased ubiquitylation and degradation of HDAC1, leading to increased acetylation of HMGB1 and its active secretion that in turn promoted mesothelial cell transformation.
more »
« less
- PAR ID:
- 10326445
- Author(s) / Creator(s):
- ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; more »
- Date Published:
- Journal Name:
- Proceedings of the National Academy of Sciences
- Volume:
- 118
- Issue:
- 48
- ISSN:
- 0027-8424
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
-
We report that ~1.8% of all mesothelioma patients and 4.9% of those younger than 55, carry rare germline variants of the BRCA1 associated RING domain 1 (BARD1)gene that were predicted to be damaging by computational analyses. We conducted functional assays, essential for accurate interpretation of missense variants, in primary fibroblasts that we established in tissue culture from a patient carrying the heterozygousBARD1V523Amutation. We found that these cells had genomic instability, reduced DNA repair, and impaired apoptosis. Investigating the underlying signaling pathways, we found that BARD1 forms a trimeric protein complex with p53 and SERCA2 that regulates calcium signaling and apoptosis. We validated these findings inBARD1-silenced primary human mesothelial cells exposed to asbestos. Our study elucidated mechanisms ofBARD1activity and revealed that heterozygous germlineBARD1mutations favor the development of mesothelioma and increase the susceptibility to asbestos carcinogenesis. These mesotheliomas are significantly less aggressive compared to mesotheliomas in asbestos workers.more » « less
-
Mesothelioma is a rare and aggressive cancer linked to asbestos exposure and characterized by rapid metastasis and poor prognosis. Inhibition of adenosine deaminase acting on dsRNA 2 (ADAR2) RNA binding but not ADAR2 editing has shown antitumor effects in mesothelioma. Natural compounds from the Traditional Chinese Medicine (TCM) database were docked to the RNA-binding interface of ADAR2’s second dsRNA binding domain (dsRBD2), and their drug-likeness and predicted safety were assessed. Eight ligands (ZINC000085597263, ZINC000085633079, ZINC000014649947, ZINC000034512861, ZINC000070454124, ZINC000085594944, ZINC000085633008, and ZINC000095909822) showed high binding affinity to dsRBD2 from molecular mechanics Poisson–Boltzmann surface area (MM/PBSA) calculations. Protein–ligand interactions were analyzed to identify key residues contributing to these binding affinities. Molecular dynamics (MD) simulations of dsRBD–ligand–RNA complexes revealed that four compounds (ZINC000085597263, ZINC000085633079, ZINC000014649947, and ZINC000034512861) had negative binding affinities to dsRBD2 in the presence of the RNA substrate GluR-2. Key residues, including Val164, Met165, Lys209, and Lys212, were crucial for ligand binding, even with RNA present, suggesting these compounds could inhibit dsRBD2’s RNA-binding function. The predicted biological activities of these compounds indicate potential anticancer properties, particularly for the treatment of mesothelioma. These compounds are structurally similar to known anti-mesothelioma agents or anticancer drugs, highlighting their therapeutic potential. Current mesothelioma treatments are limited. Optimization of these compounds, alone or in combination with current therapeutics, has potential for mesothelioma treatment. Additionally, five high-quality full-length ADAR2 models were developed. These models provide insights into ADAR2 function, mutation impacts, and potential areas for protein engineering to enhance stability, RNA-binding specificity, or protein interactions, particularly concerning dimerization or complex formation with other proteins and RNAs.more » « less
-
The transcriptional co-activator YAP1 (yes-associated protein 1), a crucial effector of the Hippo pathway in mammals, regulates cell growth, cell motility, cell migration, and carcinogenesis. The STK4/Hippo kinase phosphorylates Ser127 and inactivate YAP1 activity in mammalian cells. Cytokines such as receptor activator of nuclear factor Kappa B (RANKL) regulate the immune system and bone remodeling. Similarly, stroma-cell derived factor 1 alpha (SDF1α) produced by the bone marrow stromal cell, is directly linked to cell migration and metastasis. We hypothesize that RANKL/SDF1α attenuates phospho-Ser127 and enhances YAP nuclear localization. We conducted immunological assays to evaluate the effects of SDF1α or RANKL on YAP1 in the LNCaP prostate cancer cell line. We showed that SDF1α and RANKL modulate phospho-Ser127 and total YAP1 protein in a time-dependent manner, as demonstrated by western blotting. We also showed that SDF1α exposure promoted YAP1 nuclear localization, as revealed by immunofluorescence imaging with confocal microscopy. These findings suggest that cytokines positively regulate YAP1 activity, possibly by counteracting with the STK4/Hippo signaling. The results of this study imply that cytokines secreted by the tumor cell environment promote an invasive cancer cell phenotype by modulating the Hippo-YAP1 pathway.more » « less
-
Sex comb on midleg-like-2 (SCML2), a conserved polycomb group protein, functions as a transcriptional repressor. SCML2 binds monomethylated lysine residues on histones and regulates homeotic gene expression during development in mammals and the fly. Using proteomic approaches, we have identified SCML2 as a binding partner of the YAP1 protein complexes isolated from nuclei of prostate cancer cell lines. Both SCML2 and YAP1 are known to regulate basic cellular biology, including stem cell maintenance and carcinogenesis. Our western blot analysis showed that, unlike androgen receptor (AR)-negative cancerous and non-cancerous prostate epithelium, AR-positive cell lines express the high levels of SCML2, suggesting a possible link between androgen hormonal signaling and SCML2. In addition, our immunofluorescence imaging revealed that androgen hormone signaling promoted the subcellular localization of SCML2 and YAP1 proteins compared with mock control. Enzalutamide, a potent pharmacological inhibitor of AR, significantly prevented the subcellular distribution ofYAP1 and SCML2. Consistent with this observation, our proximity ligation assay demonstrated that androgen also regulated the physical interaction between SCML2 and YAP1proteins that occurred primarily in cell nuclei. Enzalutamide also prevented protein-protein interaction between YAP and SCML2. Besides, our GST-pulldown assay revealed that SCML2 and proteins physically interact with each other in the test tube. Furthermore, our promoter-reporter assay showed that transfection of two different SCML2 siRNA enhanced the activation of the YAP-responsive promoter-reporter gene four-fold compared to mock siRNA control. These observations suggest that the interaction between SCML2 and YAP1 is biologically functional and crucial in human physiology and disease.more » « less
- Free Publicly Accessible Full Text
-
Accepted Manuscript1.0
- Journal Article:
- https://doi.org/10.1073/pnas.2111946118
